ClinicalTrials.gg
CompletedNCT01803282Updated Jun 2, 2020Results posted

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Andecaliximab and Gemcitabine in Pancreatic Cancer, Non-small Cell Lung Cancer and Esophagogastric Cancer, sponsored by Gilead Sciences. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
236
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 300 open to participants now, 474 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
154th of 1,574
236 · median 37
Started
2013
with 76 others
Phase 1
556 of 1,851
76 open now
Registered
713th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 154th largest by enrollment of the 1,574 interventional ones that give a count, is one of 77 that started in 2013, is one of 556 in phase 1, and was the 713th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

300 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

295 more — sign in →

All 300 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy.

The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part.

Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory to or intolerant to standard therapy or for which no standard therapy exists. In Part A, participants will receive andecaliximab only.

Part B is a dose expansion to obtain additional safety and tolerability data for andecaliximab in participants with advanced pancreatic adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, esophagogastric adenocarcinoma, colorectal cancer, or breast cancer. In Part B, participants will receive andecaliximab in combination with standard-of-care chemotherapy.

03

Conditions studied

  • Pancreatic Cancer
  • Non-small Cell Lung Cancer
  • Esophagogastric Cancer
  • Colorectal Cancer
  • Breast Cancer

Keywords

  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Part A: or cytologically confirmed advanced malignant solid tumor that is to or intolerant of standard therapy or for which no standard therapy is available
  • Part B: Pancreatic Adenocarcinoma

    • Presence of histologically confirmed inoperable locally advanced or pancreatic adenocarcinoma
  • Part B: NSCLC

    • Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC
    • Absence of known epidermal growth factor receptor (EGFR) mutation
    • Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)
  • Part B: Esophagogastric Adenocarcinoma:

    • Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma
    • Human epidermal growth factor receptor 2 ()-negative tumor (primary tumor or metastatic lesion)
  • Part B: Colorectal Cancer

    • Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum
    • Radiographically measureable disease
    • No prior cytotoxic chemotherapy to treat their metastatic disease
  • Part B: Second-Line Colorectal Cancer

    • Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum
    • Radiographically measureable disease
    • Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion
  • Part B: Breast Cancer

    • Histologically or cytologically confirmed metastatic breast cancer
    • Radiographically measureable disease
    • Previous hormonal therapy for metastatic breast cancer or cytotoxic chemotherapy is allowed
    • Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician
    • HER-2 negative tumor (primary tumor or metastatic lesion)
  • Adequate organ function

Key Exclusion Criteria:

  • Pregnant or lactating
  • Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic
  • Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months
  • Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    Part A: ADX 200 mg

    Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab

  • Experimental
    Part A: ADX 600 mg

    Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab

  • Experimental
    Part A: ADX 1800 mg

    Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug

    Drug: Andecaliximab

  • Experimental
    Part B: PAC, ADX 800 mg

    Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Part B: LAC, ADX 1200 mg

    Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Part B: LSC, ADX 1200 mg

    Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Part B: EGC, ADX 800 mg

    Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} \[mFOLFOX6\], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Leucovorin · Drug: Oxaliplatin · Drug: 5-FU

  • Experimental
    Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg

    Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Leucovorin · Drug: Oxaliplatin · Drug: 5-FU · Drug: Bevacizumab

  • Experimental
    Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg

    Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Leucovorin · Drug: Oxaliplatin · Drug: 5-FU · Drug: Bevacizumab

  • Experimental
    Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg

    Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU \[FOLFIRI\] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Leucovorin · Drug: 5-FU · Drug: Bevacizumab · Drug: Irinotecan

  • Experimental
    Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg

    Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Leucovorin · Drug: 5-FU · Drug: Bevacizumab · Drug: Irinotecan

  • Experimental
    Part B: BRCA, ADX 800 mg

    Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Paclitaxel

Interventions

  • Administered intravenous infusion

    Also known as: GS-5745

  • Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle

  • Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle

  • Administered intravenously on Day 1 of each 21-day treatment cycle

  • Administered intravenously on Day 1 of each 21-day treatment cycle

  • Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • Drug5-FU

    Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

  2. Percentage of Participants Experiencing Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.

    Time frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

07

Results

Posted May 4, 2020

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 29 March 2013. The last study visit occurred on 23 April 2019.

Participant flow — Overall Study
MilestonePart A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mg
Started43636111041461145815
Completed000000000000
Not completed43636111041461145815
Withdrew: Progressive disease43622582324329611
Withdrew: Death000021151100
Withdrew: Withdrew consent000610831501
Withdrew: Investigator's discretion0007217106710
Withdrew: Adverse event000000120103
Withdrew: Non-compliance with study drug000100000000
Withdrew: Unknown reason000000010000
Withdrew: Specified criteria for withdrawal000000000110
Withdrew: Enrolled but never treated000010110100

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame:
Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
percentage of participantsPart A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mg
Percentage of Participants Experiencing Treatment-Emergent Adverse Events100.0100.083.3100.0100.0100.0100.0100.0100.0100.0100.0100.0
PrimaryPercentage of Participants Experiencing Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.

Time frame:
Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Laboratory Abnormalities
percentage of participantsPart A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mg
Any Laboratory abnormalities: Hematology0.033.333.397.290.080.087.584.490.995.5100.086.7
Any Laboratory abnormalities: Serum Chemistry100.066.783.388.960.070.087.595.681.886.487.566.7
Any Laboratory abnormalities: Coagulation25.00.033.338.910.010.035.037.836.445.537.540.0

Adverse events

Collected over Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: ADX 200 mg1/4 (25%)0/4 (0%)4/4 (100%)
Part A: ADX 600 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part A: ADX 1800 mg1/6 (16.7%)2/6 (33.3%)5/6 (83.3%)
Part B: PAC, ADX 800 mg8/36 (22.2%)19/36 (52.8%)36/36 (100%)
Part B: LAC, ADX 1200 mg4/10 (40%)5/10 (50%)9/10 (90%)
Part B: LSC, ADX 1200 mg3/10 (30%)6/10 (60%)10/10 (100%)
Part B: EGC, ADX 800 mg13/40 (32.5%)19/40 (47.5%)40/40 (100%)
Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg22/45 (48.9%)17/45 (37.8%)45/45 (100%)
Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg5/11 (45.5%)3/11 (27.3%)11/11 (100%)
Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg25/44 (56.8%)13/44 (29.5%)44/44 (100%)
Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg5/8 (62.5%)4/8 (50%)8/8 (100%)
Part B: BRCA, ADX 800 mg8/15 (53.3%)5/15 (33.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventPart A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mg
DyspnoeaRespiratory, thoracic and mediastinal disorders0/40/30/60/361/102/101/401/450/110/440/80/15
Duodenal obstructionGastrointestinal disorders0/40/31/61/360/100/100/400/450/110/440/80/15
Acute kidney injuryRenal and urinary disorders0/40/31/62/360/100/101/401/450/110/440/81/15
Pleural effusionRespiratory, thoracic and mediastinal disorders0/40/31/60/360/100/100/400/450/110/440/80/15
PyrexiaGeneral disorders0/40/30/65/360/100/102/400/450/110/440/80/15
Febrile neutropeniaBlood and lymphatic system disorders0/40/30/60/360/100/101/400/450/110/441/80/15
Abdominal painGastrointestinal disorders0/40/30/61/361/100/102/400/450/110/441/80/15
DiarrhoeaGastrointestinal disorders0/40/30/62/360/101/101/400/450/110/441/80/15
Large intestinal obstructionGastrointestinal disorders0/40/30/60/360/100/100/400/450/111/441/80/15
CellulitisInfections and infestations0/40/30/63/360/100/100/401/450/110/441/80/15
Most frequent other events
Showing 10 of 262
Most frequent other events
EventPart A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mg
NauseaGastrointestinal disorders1/42/32/618/363/105/1025/4033/459/1127/445/86/15
FatigueGeneral disorders2/42/30/627/365/107/1023/4036/457/1126/446/811/15
DiarrhoeaGastrointestinal disorders2/40/30/616/364/102/1019/4025/453/1128/446/85/15
AnaemiaBlood and lymphatic system disorders0/40/30/611/367/102/1012/409/451/1111/442/83/15
NeutropeniaBlood and lymphatic system disorders0/40/30/612/364/102/1016/4018/455/1112/445/86/15
Abdominal painGastrointestinal disorders0/40/31/66/360/102/105/4012/451/1111/445/83/15
ConstipationGastrointestinal disorders1/40/30/67/361/104/1014/4017/453/1112/445/87/15
AstheniaGeneral disorders1/41/30/66/360/101/104/408/452/116/445/80/15
AlopeciaSkin and subcutaneous tissue disorders0/40/30/620/362/105/104/405/451/1115/442/89/15
Oedema peripheralGeneral disorders0/40/30/620/362/100/1011/405/451/114/440/82/15

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).

Age, Customized
Age, Customized(Participants)Part A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mgTotal
Age — < 65 years20415242526833410133
Age — ≥ 65 years232218615193114599
Sex: Female, Male
Sex: Female, Male(Participants)Part A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mgTotal
Female102107491932521395
Male3342636312681962137
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mgTotal
Ethnicity — Hispanic or Latino00040144040219
Ethnicity — Not Hispanic or Latino4363210930391039812202
Ethnicity — Not Permitted00000062110111
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: ADX 200 mgPart A: ADX 600 mgPart A: ADX 1800 mgPart B: PAC, ADX 800 mgPart B: LAC, ADX 1200 mgPart B: LSC, ADX 1200 mgPart B: EGC, ADX 800 mgPart B: FL CRC, ADX 800 mg+BEV 5 mg/kgPart B: FL CRC, ADX 800 mg+BEV 10 mg/kgPart B: SL CRC, ADX 800 mg+BEV 5 mg/kgPart B: SL CRC, ADX 800 mg+BEV 10 mg/kgPart B: BRCA, ADX 800 mgTotal
Race — American Indian or Alaska Native0001001001003
Race — Asian0000011002004
Race — Black or African American00101316221118
Race — Native Hawaiian or Other Pacific Islander0000000000000
Race — White33533953135835612185
Race — Not Permitted10000063020113
Race — Other0002010112119
08

Study locations

18 sites
  • Alabama Oncology
    Birmingham, Alabama 35243, United States
  • Pinnacle Oncology Hematology
    Scottsdale, Arizona 85258, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • San Diego Pacific Oncology and Hematology Associates, Inc.
    Encinitas, California 92024, United States
  • University of Southern California (USC)
    Los Angeles, California 90033, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • UCLA Medical Center
    Santa Monica, California 90404, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Indiana University Health Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Cornell University
    New York, New York 10021, United States
  • Greenville Health System, Institute for Translational Oncology Research
    Greenville, South Carolina 29605, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt
    Nashville, Tennessee 37232, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clin Cancer Res. 2018 Aug 15;24(16):3829-3837. doi: 10.1158/1078-0432.CCR-17-2469. Epub 2018 Apr 24. PubMed 29691300 ↗
  • Lenz H, Park H, Shah MA, Berlin JD, Bruetman D, Chaves J, et al. Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer. Annals of Oncology (2018) 29 (suppl_8): viii150-viii204
  • Wainberg Z, Bendell J, Lenz H, Baron A, Berlin J, Bessudo A, et al. Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer. Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 3578-3578
  • Bendell J, Patel M, Brachmann C, Huang X, Maltzman J, Smith V, et al. Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer [Abstract 363] 2017 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
  • Brachmann C, Zhang Y, Zavodovskaya M, Hu J, Maltzman J, Smith V, et al. Evaluating collagen neoepitopes as pharmacodynamic biomarkers of GS-5745, an MMP9 inhibitor, in advanced gastric cancer [Abstract 58] 2017 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
  • Juric V, Mikels-Vigdal A, O'Sullivan C, Greenstein A, Stefanutti E, Barry-Hamilton V, et al. Inhibition of MMP9 improves anti-tumor immunity by changing the tumor microenvironment to promote T cell trafficking and activation. [Abstract 653/27]. 2017 American Association for Cancer Research Annual Meeting 110th Annual Meeting; 2017 01 April-05 April; Washington, DC
  • Zavodovskaya M, Zhang Y, Xiao Y, Maltzman J, Smith V, Brachmann C, et al. Exploratory Serum Biomarker Analysis in Gastric Cancer Patients Treated with GS-5745, an MMP9 Inhibitor, in Combination with mFOLFOX6 [Abstract 4463/24]. 2017 American Association for Cancer Research Annual Meeting 110th Annual Meeting; 2017 01 April-05 April; Washington, DC
  • Bendell J, Huang X, Smith V, Maltzman J, Starodub A. Results of a phase I study of GS-5745 in combination with gemcitabine and nab-paclitaxel in patients (pts) with advanced pancreatic cancer [abstract e15683] 2016. J Clin Oncol 34 supplemental
  • Shah M, Starodub A, Wainberg Z, Smith V, Maltzman J, Bendell J. Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric / GE junction tumors [Poster 4033]. American Society of Clinical Oncology (ASCO) 52nd Annual Meeting; 2016 03 June- 07 June; Chicago, IL
  • Bendell J, Starodub A, Sharma S, Wainberg Z, Shah M, Thai D. Phase I Study of GS-5745 Alone and in Combination with Chemotherapy in Patients with Advanced Solid Tumors [Poster 4030]. American Society of Clinical Oncology (ASCO) 51st Annual Meeting; 2015 29 May-02 June; Chicago, IL
  • Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, Lee M, O'Sullivan C, Barry-Hamilton V, Ghermazien H, Mikels-Vigdal A, Garcia CA, Jorgensen B, Velayo AC, Wang R, Adamkewicz JI, Smith V. Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One. 2015 May 11;10(5):e0127063. doi: 10.1371/journal.pone.0127063. eCollection 2015. PubMed 25961845 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Apr 2019, 72 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 72 months is above that.

Counting every sponsor, half of 379 studies reached it within 45 months; a quarter within 32 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2013
First posted
Mar 4, 2013
StartActual
Mar 29, 2013
Primary completionActual
Apr 23, 2019
CompletionActual
Apr 23, 2019
Results first posted
May 4, 2020
Last update
Jun 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01803282
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 4, 2013
Start date
Mar 29, 2013
Primary completion
Apr 23, 2019
Completion
Apr 23, 2019
Results posted
May 4, 2020
Last update
Jun 2, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion